PRIM, S.A. in brief
PRIM, S.A. is a listed company in the Medical Instruments industry, based in Spain. Its last known market value was $200 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $284 M and a net profit of $19 M, about 7 cents of profit for every dollar of sales. Its shares trade under the symbol 5P1.F (Frankfurt).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
PRIM, S.A. timeline
- 1966
- 🏁· approximateIncorporated as Prim, S.A.
- 2015
- •Legal Entity Identifier issuedLEI 959800M75M81U0Y2UX24 registered.
Events of PRIM, S.A. from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Spain: #87 (Jan 2020) · #86 (Jan 2021) · #91 (Jan 2022) · #91 (Dec 2022) · #96 (Jul 2023) · #94 (Jan 2024)
Key ratios
- P/E ratio
- —
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- 6.6%
- Operating margin
- 8.9%
- Return on equity
- 11.6%
- Liabilities / assets
- 30.0%
- Revenue growth
- +12.5%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $284M | +12.5% | $25M | $19M | 6.6% |
| Dec 2024 | $252M | — | $17M | $12M | 4.7% |
Annual results
- Revenue
- $284 M
- Operating income
- $25 M
- Net income
- $19 M
For year ending December-2025 · source: official annual report (ESEF)
Balance sheet
- Total assets
- $231 M
- Total liabilities
- $69 M
- Total equity
- $162 M
As of December-2025
Mutual funds holding PRIM, S.A.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Low-Priced Stock FundFidelity Management & Research Company LLC | 1.28 M | $20 M | — | 0.08% | −0.1% | Jul 31, 2026 |
| 🇺🇸 Fidelity Low-Priced Stock K6 FundFidelity Management & Research Company LLC | 146,063 | $2 M | — | 0.05% | +1.2% | Jul 31, 2026 |
| 🇺🇸 The Continental Small Company SeriesDimensional Fund Advisors LP | 40,283 | $1 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Core Equity 2 PortfolioDimensional Fund Advisors LP | 7,234 | $0 M | — | <0.01% | +2.9% | Jul 31, 2026 |
| 🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 5,801 | $0 M | — | <0.01% | +16% | Jul 31, 2026 |
| 🇺🇸 Brighthouse/Dimensional International Small Company PortfolioBrighthouse Investment Advisers, LLC | 3,013 | $0 M | — | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Siit Screened World Equity Ex-Us FundSEI INVESTMENTS MANAGEMENT CORPORATION | 2,205 | $0 M | — | 0.02% | no change | May 31, 2026 |
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 1,285 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP | 1,123 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 International Social Core Equity PortfolioDimensional Fund Advisors LP | 853 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP | 846 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP | 28 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional International Sustainability Core 1 ETFDimensional Fund Advisors LP | 4 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional International Core Equity 2 ETFDimensional Fund Advisors LP | 8 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional International Core Equity Market ETFDimensional Fund Advisors LP | 4 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 15 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Ownership and subsidiaries
- ESTABLECIMIENTOS ORTOPEDICOS PRIM SA🇪🇸 Móstoles
PRIM, S.A. scorecard#
Passes 3 of the 4 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth1 of 1
- ✓Revenue grew in the newest year12.5%Revenue up 12.5% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability2 of 3
- ✓Profitable in the newest year$19 MNet income $19 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✓Operating margin above its peers' median8.9%8.9% against Medical Instruments's median of 7.2% (46 companies).
- ✗Return on equity above 15%12.7%12.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial healthnot known
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (esef), the medians of Medical Instruments, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from PRIM, S.A.'s statements, beside the median of Medical Instruments.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 8.9% | 7.2% | |
| Net margin | 6.6% | 3.8% | |
| Return on equity | 12.7% | 3.5% | |
| Revenue growth | 12.5% | 8.9% |
Margins, returns, growth, debt and cash flow over 5 years.
PRIM, S.A.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in EUR millions; per-share figures in EUR; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 252+8.0%100% | 233+7.7%100% | 217+9.8%100% | 197+17.1%100% | 169—100% | |
| Cost of revenue | 103−1.1%41.0% | 104+12.5%44.7% | 93+2.6%42.8% | 90+18.6%45.8% | 76—45.2% | |
| Total costs and expenses | 232+5.2%92.0% | 220+8.0%94.4% | 204+7.0%94.1% | 191+25.2%96.6% | 152—90.3% | |
| Operating income | 22+43.0%8.9% | 16−2.5%6.7% | 16+71.2%7.4% | 9.4−46.1%4.7% | 17—10.3% | |
| Interest and finance income | 0.6+18.7%0.2% | 0.5−10.6%0.2% | 0.5−51.5%0.2% | 1.1−5.2%0.6% | 1.2—0.7% | |
| Interest expense and finance costs | 0.5−30.5%0.2% | 0.8−6.4%0.3% | 0.8+194%0.4% | 0.3+108%0.1% | 0.1—0.1% | |
| Share of profit of associates | 0—0.0% | −0.1—−0.0% | −0.0—−0.0% | −0.1—−0.0% | 0—0.0% | |
| Income before tax | 22+52.1%8.7% | 14−15.8%6.1% | 17+56.6%7.9% | 11−52.8%5.5% | 23—13.7% | |
| Income tax | 5.1+50.0%2.0% | 3.4−21.5%1.5% | 4.4+75.4%2.0% | 2.5−56.0%1.3% | 5.6—3.3% | |
| Income from continuing operations | 17+52.8%6.6% | 11−13.8%4.7% | 13+51.0%5.9% | 8.4−51.8%4.3% | 17—10.3% | |
| Net income including minority interests | 17+52.8%6.6% | 11−13.8%4.7% | 13+51.0%5.9% | 8.4−51.8%4.3% | 17—10.3% | |
| Minority interests' share of net income | — | — | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | 17+52.8%6.6% | 11−13.8%4.7% | 13+51.0%5.9% | 8.4−51.8%4.3% | 17—10.3% | |
| Earnings per share, basic | 0.98+53.1%— | 0.64—— | — | — | — | |
| Earnings per share, diluted | 0.98+53.1%— | 0.64—— | — | — | — | |
| Balance sheet | ||||||
| Cash and cash equivalents | 18+89.8%9.3% | 9.6+49.6%5.1% | 6.4−40.8%3.2% | 11−66.4%5.9% | 32—18.0% | |
| Receivables | 50−0.4%25.5% | 50−18.9%26.4% | 62+34.3%31.0% | 46+24.6%25.0% | 37—20.6% | |
| Inventory | 67−4.4%34.3% | 70+2.3%37.0% | 69+4.0%34.4% | 66+6.4%35.8% | 62—34.6% | |
| Current assets | 141+4.5%71.7% | 135−6.6%70.9% | 144+10.0%72.2% | 131−3.4%71.0% | 136—75.6% | |
| Property, plant and equipment | 21+12.5%10.7% | 19+6.3%9.9% | 18+4.2%8.8% | 17+9.5%9.1% | 15—8.6% | |
| Right-of-use (leased) assets | 6.9+0.7%3.5% | 6.9+2.4%3.6% | 6.7−0.1%3.4% | 6.7+20.5%3.6% | 5.6—3.1% | |
| Goodwill | 11+0.9%5.8% | 11+19.2%6.0% | 9.5+4.0%4.8% | 9.2+86.0%5.0% | 4.9—2.7% | |
| Other intangible assets | 12−8.2%6.0% | 13−10.2%6.7% | 14+45.0%7.1% | 9.8+123%5.3% | 4.4—2.4% | |
| Investments in associates | 0−100%0.0% | 0.3−82.0%0.1% | 1.4−1.1%0.7% | 1.4—0.8% | 0—0.0% | |
| Non-current assets | 56+0.5%28.3% | 55−0.4%29.1% | 56+3.7%27.8% | 54+22.1%29.0% | 44—24.4% | |
| Total assets | 197+3.3%100% | 190−4.9%100% | 200+8.2%100% | 185+2.9%100% | 180—100% | |
| Accounts payable | 37−3.2%18.8% | 38−13.1%20.1% | 44+23.3%22.0% | 36−4.0%19.3% | 37—20.7% | |
| Debt due within a year | 9.0−17.7%4.6% | 11−35.5%5.8% | 17+65.0%8.5% | 10+28.6%5.6% | 8.0—4.4% | |
| Current liabilities | 47−4.7%23.9% | 49−20.4%26.0% | 62+27.5%31.0% | 49+6.1%26.3% | 46—25.5% | |
| Long-term debt | 7.2−4.7%3.7% | 7.6−10.8%4.0% | 8.5−28.0%4.2% | 12+6.6%6.4% | 11—6.1% | |
| Non-current liabilities | 12−0.9%6.0% | 12−2.0%6.3% | 12−26.5%6.1% | 17+32.9%9.0% | 12—6.9% | |
| Shareholders' equity | 138+6.8%70.0% | 129+2.5%67.8% | 126+5.1%62.9% | 120−1.5%64.7% | 121—67.5% | |
| Minority interests | 0−100%0.0% | 0.0−91.3%0.0% | 0.0−5.4%0.0% | 0.0−23.9%0.0% | 0.0—0.0% | |
| Total equity | 138+6.8%70.0% | 129+2.5%67.8% | 126+5.1%62.9% | 120−1.5%64.7% | 121—67.5% | |
| Total liabilities and equity | 197+3.3%100% | 190−4.9%100% | 200+8.2%100% | 185+2.9%100% | 180—100% | |
| Cash-flow statement | ||||||
| Capital expenditure | −1.3—−0.5% | 0—0.0% | −8.8—−4.0% | −12—−6.0% | −12—−6.9% | |
| Intangible assets bought | — | — | −1.6—−0.8% | −0.1—−0.1% | −0.9—−0.5% | |
| Acquisitions, net of cash acquired | 0—0.0% | −1.0—−0.4% | −2.8—−1.3% | −5.2—−2.6% | −0.4—−0.2% | |
| Cash from investing activities | −10—−4.0% | −7.5—−3.2% | −3.7—−1.7% | −14—−7.1% | −8.7—−5.2% | |
| Debt issued | 9.2−32.3%3.7% | 14—5.8% | 0−100%0.0% | 2.0—1.0% | 0—0.0% | |
| Debt repaid | −12—−4.8% | −17—−7.3% | −0.0—−0.0% | −1.0—−0.5% | 0—0.0% | |
| Shares bought back | −0.4—−0.2% | 0—0.0% | — | — | — | |
| Dividends paid | −8.0—−3.2% | −7.6—−3.3% | −6.2—−2.9% | −8.8—−4.5% | −5.4—−3.2% | |
| Cash from financing activities | −12—−4.6% | −11−137%−4.9% | 30—14.0% | −12—−6.2% | −15—−9.0% | |
| Exchange-rate effect on cash | −0.1−3640%−0.0% | 0.0−97.1%0.0% | 0.1—0.1% | −0.1—−0.0% | −0.1—−0.1% | |
| Change in cash | 8.7+171%3.4% | 3.2—1.4% | −4.4—−2.0% | −21−3903%−10.9% | 0.6—0.3% | |
| Report | ESEF | ESEF | ESEF | ESEF | ESEF | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
How PRIM, S.A. compares in Medical Instruments
- Revenue$284 M · higher than 38% of 120
- Net margin6.6% · higher than 41% of 114
- Revenue growth12.5% · higher than 67% of 49
Peer comparison · Medical Instruments
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| PRIM, S.A.🇪🇸 | $200 M | — | 6.6% | +12.5% |
| Intuitive Surgical, Inc.🇺🇸 | $155.6 B | 52.6× | 25.5% | +20.5% |
| EssilorLuxottica S.A.🇫🇷 | $88.0 B | 32.1× | 8.1% | +4.5% |
| HOYA Corporation🇯🇵 | $56.2 B | 32.8× | 25.4% | — |
| Becton, Dickinson and Company🇺🇸 | $54.0 B | 57.4× | 4.2% | +8.2% |
| Alcon Inc.🇨🇭 | $37.1 B | 37.9× | 9.4% | +4.9% |
| ResMed Inc.🇺🇸 | $35.3 B | 22.1× | 27.8% | +9.8% |
| West Pharmaceutical Services, Inc.🇺🇸 | $27.1 B | 42.4× | 18.8% | +6.3% |
| Terumo Corporation🇯🇵 | $24.9 B | 27.0× | 12.0% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Intuitive Surgical, Inc.$155.6 B
- EssilorLuxottica S.A.$88.0 B
- HOYA Corporation$56.2 B
- Becton, Dickinson and Company$54.0 B
- Alcon Inc.$37.1 B
- ResMed Inc.$35.3 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 15, 2026
Figures from Official annual report (ESEF), value.today research, GLEIF register.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at PRIM, S.A.? Verify and update this profile — free
Show PRIM, S.A.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.